Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
90 hedge funds and large institutions have $47.5M invested in Endocyte, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 25 increasing their positions, 31 reducing their positions, and 9 closing their positions.
554% more call options, than puts
Call options by funds: $353K | Put options by funds: $54K
4% less capital invested
Capital invested by funds: $49.4M → $47.5M (-$1.92M)
6% less funds holding
Funds holding: 96 → 90 (-6)
19% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 31
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$589K |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$545K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$489K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$427K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$341K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$815K |
| 2 |
Millennium Management
New York
|
-$479K |
| 3 |
JP Morgan Chase
New York
|
-$190K |
| 4 |
EGA
Eagle Global Advisors
Houston,
Texas
|
-$168K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$140K |
ECYT Hedge Fund Activity: Q3 2016 in Review
90 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q3 2016, worth a combined $47.5M — down 3.9% from $49.4M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ECYT and 4 opened new positions — a net loss of 5 holders — while 31 trimmed existing stakes and 25 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $589K. The largest seller was Baker Bros. Advisors, cutting an estimated $815K.
- 90 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q3 2016, down from 96 in Q2 2016.
- Funds reported $47.5M of Endocyte, Inc. Common Stock stock for Q3 2016, down 3.9% quarter-over-quarter.
- 4 funds opened new Endocyte, Inc. Common Stock positions in Q3 2016 and 9 closed out, a net change of -5 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q3 2016 was Renaissance Technologies, an estimated $589K added.
- The largest Endocyte, Inc. Common Stock seller in Q3 2016 was Baker Bros. Advisors, an estimated $815K sold.
Based on aggregated 13F filings for Q3 2016.